OSSTEC raises $8M to bring cementless partial knee to the US
What's the deal? UK orthopedic startup OSSTECDealroom has a profile for this one. Try Dealroom → has closed an $8 million early-stage round to fund the first-in-human US surgical cases of ASCENT, its cementless, fixed-bearing partial knee system. EMBRYO VenturesDealroom has a profile for this one. Try Dealroom → led, with Neovate Capital, New Wave VenturesDealroom has a profile for this one. Try Dealroom →, Oxford Technology Innovation Finance, and Empirical VenturesDealroom has a profile for this one. Try Dealroom → participating.
What's the endgame? OSSTEC, spun out of Imperial College London in 2021, builds 3D-printed implants designed for biological fixation without cement. The capital will take ASCENT and its CLARITY instruments through FDA clearance toward first-in-human procedures planned for the first half of 2027.
Why now? Around half of knee replacement patients suit a partial knee, yet only about 10% receive one. OSSTEC argues cement adds time and complexity, while cementless fixation reduces loosening — a leading cause of revision.
What's the context? The round follows OSSTEC's earlier move to set up US operations and add orthopedic veteran Dr. Nick Pachuda to its board. US operations are led by commercial lead Christopher Campbell, positioning the company in the world's largest orthopedic market ahead of entry.
What did they say? "This financing moves our focus from preparation to patients," said founder and chief executive officer Max Munford. The company is also expanding a pipeline of cementless applications beyond the knee and evaluating integration with robotic surgery platforms.
What could go wrong? ASCENT and CLARITY are not yet FDA-cleared or available for sale in the US. The round funds a costly regulatory and clinical step, with little evidence yet of clinical performance.
The signal: At $8 million, this is a sizeable early-stage raise — in the 80th percentile by amount for its stage. But the milestones that matter are clearance and initial human results, not an immediate commercial launch.
Read more: business.theantlersamerican.com
Image credit: OSSTEC
